Mr. Eric So reports

CYBIN TO TRANSFER U.S. STOCK EXCHANGE LISTING TO NASDAQ

Cybin Inc. will voluntarily transfer its United States stock exchange listing to the Nasdaq Global Market from the NYSE American LLC. The company expects that its common shares will cease trading on the NYSE American at market close on Jan. 4, 2026, and commence trading on Nasdaq at market open on Jan. 5, 2026.

Concurrent with the commencement of trading on Nasdaq, the company will no longer trade under the ticker symbol CYBN and instead will trade under the ticker symbol HELP. The company will continue to be listed on the Cboe Canada and will also trade under the new HELP ticker symbol commencing on Jan. 5, 2026.

"We are pleased to join the community of global pharmaceutical companies listed on Nasdaq and thank the NYSE American for supporting the company over the last four years since our initial listing," said Eric So, interim chief executive officer of Cybin. "The transfer to Nasdaq marks the next step in the evolution of Cybin into a global pharmaceutical company."

About Cybin Inc.

Cybin is a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The company is currently developing CYB003, in phase 3 studies for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the United States Food and Drug Administration and CYB004 in phase 2 study for generalized anxiety disorder. Cybin also has an extensive research pipeline of investigational compounds.

We seek Safe Harbor.